The maker of Ozempic and Wegovy just made the biggest AI bet in its 100-year history.
Novo Nordisk announced a strategic partnership with OpenAI to apply artificial intelligence across its entire business. The partnership will enable Novo to analyze complex datasets, identify promising new drugs, and reduce the time it takes for a medicine to move from the research stage to patient use. CNBC
Beyond R&D, the collaboration will extend into manufacturing, supply chain, and commercial operations. Pilot programs are expected to launch across these functions, with full integration targeted by the end of 2026. BioPharm International
Why Novo Needs This
The business context matters here. Novo Nordisk has been losing ground to US rival Eli Lilly in the high-stakes obesity drug market. In early 2026, Novo's next-generation obesity therapy CagriSema failed to match Lilly's ZepBound in late-stage trials, sending Novo's stock down roughly 16%. The OpenAI partnership is part of a broader push to accelerate its pipeline and recover momentum. Quartz
CEO Mike Doustdar said: "There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives. Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible." CNBC
Workforce and Governance
OpenAI will also help train Novo Nordisk's global workforce to improve AI literacy. Doustdar said the goal is not to reduce headcount but to make employees more productive while moderating how quickly the company needs to add new staff. "The aim here is not replacing our scientists. It's about supercharging them." Quartz
Data governance and human-in-the-loop oversight are emphasized throughout the agreement to mitigate clinical, regulatory, and ethical risks as AI capabilities expand into healthcare decision support. BioPharm International
The Broader Trend
Novo is one of several major pharma companies now running enterprise-wide AI partnerships with OpenAI. Sanofi, Moderna, Thermo Fisher, and Eli Lilly have all signed similar agreements. The global drug industry's investment in AI is estimated to reach $2.51 billion in 2026, according to Precedence Research. The race to find new drugs faster is becoming an AI race. Quartz
